Chief Financial Officer · LIGAND PHARMACEUTICALS INC · Common Stock
Side
SELL
Value
$139K
Shares
699
Price
$198.71
Executed
Mar 4, 2026
Disclosed
Mar 6, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 4 executedMar 6, 2026 disclosed
LGND · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering+10 / 15
2 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Espinoza Octavio filed this Form 4 reporting a open-market sale of LGND on Mar 4, 2026. It became public on Mar 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Espinoza Octaviocik:0001905248
Issuer
LIGAND PHARMACEUTICALS INCcik:0000886163
Revision history · 0
No field has changed since this record was first ingested.
